Sage Therapeutics (NASDAQ:SAGE) stock was higher after the clinical-stage biopharmaceutical company developing treatment for central nervous system disorders announced positive results on secondary endpoints from its phase 2 clinical trial of SAGE-547 for the treatment of severe postpartum depression. “Postpartum depression represents a severely understudied and under-diagnosed class of patients. PPD is currently estimated to affect between 500,000 and 750,000 mothers in the U.S. each year.
The unmet need for treatment in this vulnerable patient is significant,” said Steve Kanes, chief medical officer. “The results of the secondary endpoints in this phase 2 study of SAGE-547, including the Edinburgh Perinatal Depression Scale and PHQ-9, support the primary endpoints achieved in the trial.” Based on the positive results from the phase 2 clinical trial in severe PPD, Sage has expanded its development program with the initiation of two additional multi-center, placebo-controlled trials. Top-line results from these two trials are expected in 2017. Sage plans to meet with the U.S. Food and Drug Administration to discuss the development pathway for SAGE-547 in PPD.
The stock increased 0.30% or $0.14 during the last trading session, hitting $46.59. About 516,789 shares traded hands. SAGE Therapeutics Inc (NASDAQ:SAGE) has risen 51.51% since February 24, 2016 and is uptrending. It has outperformed by 39.59% the S&P500.
SAGE Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The company has a market cap of $1.73 billion. The Firm is engaged in developing and commercializing medicines to treat central nervous system disorders. It currently has negative earnings. The Company’s lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and extrasynaptic modulator of the GABAA receptor.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.